These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 26124480)

  • 1. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
    J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
    Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
    Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
    Ditzel HM; Strickland KC; Meserve EE; Stover E; Konstantinopoulos PA; Matulonis UA; Muto MG; Liu JF; Feltmate C; Horowitz N; Berkowitz RS; Gupta M; Hecht JL; Lin DI; Jochumsen KM; Welch WR; Hirsch MS; Quade BJ; Lee KR; Crum CP; Mutter GL; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2019 May; 38(3):230-240. PubMed ID: 29750700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
    Kojima N; Kuno I; Ushigusa T; Kato T; Yoshida H
    Virchows Arch; 2020 Sep; 477(3):429-436. PubMed ID: 32103350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of Paclitaxel-based hyperthermic intraperitoneal chemotherapy in advanced high-grade serous ovarian cancer patients - interim analysis of safety and immediate efficacy of a randomized control trial (C-HOC trial).
    Wang Q; Liu H; Shen Y; Shen L; Li J; Feng W
    J Ovarian Res; 2024 Jul; 17(1):145. PubMed ID: 38997720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.
    Lawson BC; Yang RK; Euscher ED; Ramalingam P; Malpica A
    Hum Pathol; 2021 Sep; 115():76-83. PubMed ID: 34153306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma.
    Said I; Böhm S; Beasley J; Ellery P; Faruqi AZ; Ganesan R; Hirschowitz L; Jeetle S; Leen SL; McCluggage WG; McDermott J; Merard R; Millner TO; Trevisan G; Vella J; Gilks CB; Singh N
    Int J Gynecol Pathol; 2017 Mar; 36(2):172-179. PubMed ID: 27362902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial.
    du Bois A; Kristensen G; Ray-Coquard I; Reuss A; Pignata S; Colombo N; Denison U; Vergote I; Del Campo JM; Ottevanger P; Heubner M; Minarik T; Sevin E; de Gregorio N; Bidziński M; Pfisterer J; Malander S; Hilpert F; Mirza MR; Scambia G; Meier W; Nicoletto MO; Bjørge L; Lortholary A; Sailer MO; Merger M; Harter P;
    Lancet Oncol; 2016 Jan; 17(1):78-89. PubMed ID: 26590673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
    Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602.
    Onda T; Satoh T; Saito T; Kasamatsu T; Nakanishi T; Nakamura K; Wakabayashi M; Takehara K; Saito M; Ushijima K; Kobayashi H; Kawana K; Yokota H; Takano M; Takeshima N; Watanabe Y; Yaegashi N; Konishi I; Kamura T; Yoshikawa H;
    Eur J Cancer; 2016 Sep; 64():22-31. PubMed ID: 27323348
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer.
    Mendivil AA; Micha JP; Brown JV; Rettenmaier MA; Abaid LN; Lopez KL; Goldstein BH
    Int J Gynecol Cancer; 2013 Mar; 23(3):533-9. PubMed ID: 23385285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.